Catalyst
Slingshot members are tracking this event:
Abeona Therapeutics' (ABEO) gene therapy EB-101 for rare skin-blistering disorder designated by the FDA as orphan drug
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABEO | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 25, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Eb-101, Orphan Drug, Skin-blistering Disorder
